Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

Phase 4

Not yet recruiting

• Conditions: Metastatic Biliary Tract Cancer; HER2 Positive
• Interventions: Drug: Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor

• Registration Number: NCT06818773
• Lead Sponsor: Eastern Hepatobiliary Surgery Hospital

Brief Summary

To evaluate the efficacy and safety of inetetamab in combination with chemotherapy ± immunotherapy as a first-line treatment for HER2-positive advanced biliary tract cancer, providing theoretical evidence and practical guidance for further optimizing treatment regimens and improving therapeutic outcomes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-12-29
• Status Verified: 2025-02
• Study Start: 2025-02
• Study First Submitted QC: 2025-02-07
• Last Update Submitted: 2025-02-07
• Study First Posted: 2025-02-10
• Last Update Posted: 2025-02-10
• Primary Completion: 2026-12-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• Males or females aged ≥18 years;
• Histologically confirmed HER2-positive metastatic biliary tract cancer;
• ECOG performance status of 0 to 1;
• No prior treatment with anti-HER2 therapies;
• Patients have not received any systemic anticancer treatment in the recurrent/metastatic setting;
• Patients who have experienced disease recurrence more than 6 months after curative surgery; if adjuvant therapy (chemotherapy and/or radiotherapy) was received post-surgery, patients must have had recurrence more than 6 months after completion of adjuvant therapy;
• Presence of at least one measurable lesion;
• Adequate function of major organs as defined by the following criteria;
• Estimated survival of ≥3 months;
• Voluntary participation in this study, signing of the informed consent form, good compliance, and willingness to cooperate with follow-up.

Exclusion Criteria

• Known allergy or contraindication to any component of the study drugs;
• Previous treatment with anti-HER2 therapies;
• Prior use of immunotherapy;
• Use of immunosuppressive agents within 14 days before the first dose, except:

Intranasal, inhaled, topical steroids, or local injections (e.g., intra-articular) Systemic corticosteroids ≤10 mg/day prednisone or equivalent Steroids for hypersensitivity reactions (e.g., premedication for CT scans)

• Known active central nervous system metastases or carcinomatous meningitis;
• Other malignancies within 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell skin cancer;
• Major surgery or significant trauma within 4 weeks before randomization, or planned major surgery;
• Severe cardiac disease;
• Resting dyspnea due to tumor progression or comorbidities, or requiring supplemental oxygen;
• Neuropathy ≥ Grade I per NCI criteria;
• Active interstitial lung disease (ILD) or pulmonary disease requiring bronchodilators;
• History of immunodeficiency;
• Participation in another drug trial within 4 weeks before screening;
• Pregnant or breastfeeding women, or women of childbearing potential with a positive pregnancy test at screening; unwillingness to use effective contraception during and for 6 months after the study;
• Any serious concomitant illness or conditions that may interfere with the planned therapy or render participation unsuitable.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
inetetamab+ Gemcitabine + Cisplatin ± PD-1/PD-L1 Inhibitor	Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor	-

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	12 months

Secondary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS)	12 months
Quality of Life Questionnaire-Core 30（QLQ-C30）	24months
Adverse Event（AE）	24 months
Disease Control Rate (DCR)	12 months
Overall Survival (OS)	24 months